These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26691296)

  • 41. Energy metabolism in amyotrophic lateral sclerosis.
    Dupuis L; Pradat PF; Ludolph AC; Loeffler JP
    Lancet Neurol; 2011 Jan; 10(1):75-82. PubMed ID: 21035400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Amyotrophic lateral sclerosis--electrophysiologic aspects of its pathophysiology and new therapeutic options].
    Kuwabara S
    Brain Nerve; 2010 Aug; 62(8):885-91. PubMed ID: 20714037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons.
    Chou SM; Norris FH
    Muscle Nerve; 1993 Aug; 16(8):864-9. PubMed ID: 8332139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The future of motor neuron disease: the challenge is in the genes.
    Veldink JH; Van den Berg LH; Wokke JH
    J Neurol; 2004 Apr; 251(4):491-500. PubMed ID: 15083302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis].
    Van den Bosch L
    Verh K Acad Geneeskd Belg; 2006; 68(4):249-69. PubMed ID: 17214440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Utility of muscle ultrasonography for the diagnosis of amyotrophic lateral sclerosis].
    Misawa S
    Brain Nerve; 2014 Mar; 66(3):229-36. PubMed ID: 24607947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
    JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amyotrophic lateral sclerosis--the tools of the trait.
    Lederer CW; Santama N
    Biotechnol J; 2007 May; 2(5):608-21. PubMed ID: 17345579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms.
    Tang BL
    Rev Neurosci; 2017 Oct; 28(7):725-738. PubMed ID: 28599400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease?
    Neusch C; Bähr M; Schneider-Gold C
    Muscle Nerve; 2007 Jun; 35(6):712-24. PubMed ID: 17373702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies.
    Vucic S; Rothstein JD; Kiernan MC
    Trends Neurosci; 2014 Aug; 37(8):433-42. PubMed ID: 24927875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New therapeutic targets for amyotrophic lateral sclerosis.
    Kuzma-Kozakiewicz M; Kwiecinski H
    Expert Opin Ther Targets; 2011 Feb; 15(2):127-43. PubMed ID: 21133819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice.
    Teuling E; van Dis V; Wulf PS; Haasdijk ED; Akhmanova A; Hoogenraad CC; Jaarsma D
    Hum Mol Genet; 2008 Sep; 17(18):2849-62. PubMed ID: 18579581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Research in amyotrophic lateral sclerosis: what is new in 2009?].
    Pradat PF; Attarian S; Camdessanché JP; Carluer L; Cintas P; Corcia P; Echaniz-Laguna A; Gonzalez-Bermejo J; Guy N; Nicolas G; Perez T; Soriani MH; Vandenberghe N; Verschueren A;
    Rev Neurol (Paris); 2010; 166(8-9):683-98. PubMed ID: 20472259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive impairment in amyotrophic lateral sclerosis.
    Phukan J; Pender NP; Hardiman O
    Lancet Neurol; 2007 Nov; 6(11):994-1003. PubMed ID: 17945153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TDP-43 in differential diagnosis of motor neuron disorders.
    Dickson DW; Josephs KA; Amador-Ortiz C
    Acta Neuropathol; 2007 Jul; 114(1):71-9. PubMed ID: 17569066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.
    Krüger T; Lautenschläger J; Grosskreutz J; Rhode H
    Proteomics Clin Appl; 2013 Jan; 7(1-2):123-35. PubMed ID: 23129563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis.
    Vucic S; Cheah BC; Kiernan MC
    Exp Neurol; 2009 Nov; 220(1):177-82. PubMed ID: 19716820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical features of amyotrophic lateral sclerosis and their prognostic value.
    Tard C; Defebvre L; Moreau C; Devos D; Danel-Brunaud V
    Rev Neurol (Paris); 2017 May; 173(5):263-272. PubMed ID: 28477850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
    Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
    Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.